U.S. License Holder:
Centocor Ortho Biotech Inc. (Janssen Biotech, Inc.)
Date of License:
STELARA (ustekinumab) is a human interleukin-12 and -23 antagonist indicated for the treatment of:
Adult patients with:
Moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy;
Active psoriatic arthritis (PsA), alone or in combination with methotrexate;
Moderately to severely active Crohn's disease (CD);
Moderately to severely active ulcerative colitis;
Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
6,914,128 (Human Antibodies that Bind Human IL-12 and Methods for Producing) 7,504,485 (Human Antibodies that Bind Human IL-12)
Abbott Bioresearch Center, Inc.; Abbott Biotechnology Ltd; Abbott GmbH and Co. KG; AbbVie Deutschland GmbH and Co. KG; AbbVie Bioresearch Center, Inc.
Centocor Biologics LLC; Centocor Ortho Biotech, Inc. Janssen Biotech, Inc.
Federal Circuit Appeal(s)
Jury Verdict (Claims Invalid); Federal Circuit Affirmed